Allison Cardwell
Family · Kokomo, INNPI 1932755048
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 27.1% of the total. Reporting peaked in 2022 at $2,293 and has fallen 58.0% since, to $963 in 2023. Among family clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$446
- Lilly USA, LLC$424
- Bayer$394
- Esperion Therapeutics, Inc.$268
- Biohaven Pharmaceutical Holding Company Ltd.$185
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,105100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 63 | $1,113 |
| AbbVie | 43 | $446 |
| Lilly USA, LLC | 24 | $424 |
| Bayer | 24 | $394 |
| Esperion Therapeutics, Inc. | 3 | $268 |
| Biohaven Pharmaceutical Holding Company Ltd. | 23 | $185 |
| Amgen | 10 | $180 |
| AstraZeneca | 5 | $164 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $144 |
| Alkermes, Inc. | 6 | $141 |
| Biohaven Pharmaceuticals, Inc. | 3 | $128 |
| Pfizer | 6 | $117 |
| Boehringer Ingelheim | 6 | $88 |
| Corium, LLC | 4 | $77 |
| Teva Pharmaceuticals USA, Inc. | 4 | $56 |
| Novartis | 3 | $48 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| GSK | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Cranial Technologies, Inc | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,105 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levocetirizine Dihydrochloride | 15 | $128 |
Paid to pharmacies, not to this prescriber.
Other family in Kokomo
- Miranda TedderKokomo$15K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.